Yazar "Bolaman, Zahit" seçeneğine göre listele

Listeleniyor 1 - 7 / 7
  • [ X ]
    Öğe
    The Effects of Estradiol Valerate 2 mg and Dienogest 2 mg Combination on Activated Protein C Resistance in Healthy Postmenopausal Women
    (Galenos Yayincilik, 2006) Kafkas, Samet; Kalkan, Nurdan Yidiz; Bolaman, Zahit; Kalkan, Uzeyir; Odabasi, Ali R. Za; Yuksel, Hasan; Batun, Sabri
    Objective: It is aimed that, to investigate the effect of estradiol valerate and dienogest combination, which is used as a hormone replacement therapy (HRT) regimen on hemostatic parameters and activated Protein C resistance in healthy postmenopausal women. Materials and Methods: Fifty seven women received HRT treatment in four month period. The placebo group consisted of 50 women. In the HRT group 10.5% (6/57), and in the placebo group 4% (2/50) were heterozigot of FV Leiden mutation. Hemostatic parameters were investigated in only non-mutation women, to avoid potential effects of FV Leiden mutation on activated Protein C. Results: Although these changes did not reach statistical significance, a comparison of hemostatic parameters for both groups showed that in the study group (receiving 2 mg EV/2 mg DNG) FV and Protein C levels were increased, and FVIII levels were decreased compared to the placebo group. There were also no significant differences in FVII and free Protein S levels. Multiple logistic regression analysis was performed to determine the association of (2 mg EV/2 mg DNG) treatment with FV, FVII, FVIII, Protein C, free Protein S and activated Protein C sensitivity rate. There was no significant effect of these independent variables on activated Protein C sensitivity rate (p>0.05). Discussion: Combination of estradiol valerate and dienogest has no effect on activated Protein C sensitivity ratios. Hormone replacement therapy does not cause acquired activated Protein C resistance (p>0.05).
  • [ X ]
    Öğe
    Factor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T mutations in Turkish inflammatory bowel disease patients
    (H G E Update Medical Publishing S A, 2007) Yasa, Mehmet Hadi; Bolaman, Zahit; Yukselen, Vahit; Kadikoylu, Gurhan; Karaoglu, Ali Onder; Batun, Sabri
    Background/Aims: Patients with inflammatory bowel disease (IBD) have an increased risk for thromboembolic complications. We investigated the incidence of factor V Leiden G1691A, methylene tetrahydrofolate reductase (MTHFR) C677T, and prothrombin G20210A mutation in 27 Turkish IBD patients with no history of thromboembolic disease. Methodology: Twenty-seven patients, 22 with ulcerative colitis (UC) and 5 with Crohn's disease (CD), and 47 healthy were included to the study. The DNAs were obtained from peripheral blood by using pure polymerase chain kit. Then, factor V Leiden G1691A, which active protein C resistance positive, prothrombin G20210A and MTHFR C677T mutations were investigated in DNA by using LightCycler-Factor V Leiden G1691A mutation, Prothrombin G20210A and MTHFR C677T estimate kits. Results: The heterozygote factor V Leiden G1691A mutation was detected in 3 (11.1%) patients with IBD and 2 (4.3%) controls (p > 0.05). The homozygote factor V Leiden G1691A mutation was not estimated among patients and controls. Heterozygote prothrombin G20210A mutation was detected in 2 (7.4%) patients with IBD and in 0 (0%) controls (p>0.05). There was no homozygote prothrombin G20210A mutation in IBD and controls. Heterozygote MTHFR C677T mutation was 10 of 27 (37%) patients with IBD while 15 of 47 (32%) controls (p>0.05). Homozygote MTHFR C677T mutation was detected in 4 patients (14.9%) with IBD and 3 (6.3%) controls (p>0.05). Conclusions: Our study did not reveal any association between IBD and the most common hereditary thrombophilic factors and these mutations interfere with neither disease manifestations nor the thrombotic complications.
  • [ X ]
    Öğe
    Hereditary Thrombophilic Factors in Stroke Due to Cerebral Infarct
    (Elsevier Science Inc, 2009) Bolaman, Zahit; Ozkul, Ayca; Kiylioglu, Nefati; Kadikoylu, Gurhan; Erturk, Ahmet; Batun, Sabri; Akyol, Ali
    Background: The stroke is the third most common cause of all deaths. In new Studies, the importance of hereditary thrombophilic factors on stroke is emphasized. The aim of this study is to determine the role of hereditary thrombophilic factors including factor V Leiden A1691G (FVL), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T gene mutations in patients with stroke because of cerebral infarct. Methods: Twenty-four patients with stroke and 53 controls with risk factor for stroke were enrolled. Polymerase chain reaction was used to detect these mutations. Results: Heterozygote FVL mutation in 2 (8.3%) patients and MTHFR mutation in 10 (41.7%) patients were detected. In the control group, there were 2 (3.9%) patients with heterozygote FVL mutation and 15 (28.3%) patients with MTHR mutation. Both FVL and MTHFR gene Mutations were detected in I patient and 2 controls, respectively. Prothrombin gene mutation was not found in 2 groups. There were not statistically significant differences for all 3 mutation,; in-between 2 groups (P > 0.05). Odds ratios were 0.431 (0.074 2.504, 95% CI) for FVL mutation and 0.553 (0.221 1.381, 95% CI) for MTHFR mutation, respectively. Conclusion: Although our study group was small, hereditary thrombophilic factors might not be risk factors for stroke because of cerebral infarct.
  • Küçük Resim
    Öğe
    Incidence of aplastic anemia in Turkey: A hospital-based prospective multicentre study
    (1997) Başlar, Zafer; Aktuǧlu, Gülten; Bolaman, Zahit; Büyükkeçeci, Filiz; Gezer, Sefer; Kansu, Emin; Koçak, Rikkat; 00000003-0651-5462
    The incidence of aplastic anemia among hospitalized adult patients was prospectively determined in this first study in Turkey. New cases of aplastic anemia among patients 14 years and older who were admitted to the study centers were included in a 3 year survey. Seventy-three patients fulfilled the diagnostic criteria, yielding a mean annual incidence rate of 1.14 cases in 103 admissions. The male-to-female ratio of the cases (1.6:1) differed from the almost equal ratio of the larger population of Turkey. The median age was 30 years and females were younger at diagnosis. The age distribution of the cases was different from that of the population; showing two incidence peaks in both sexes. The majority of the patients (89%) had severe disease.
  • Küçük Resim
    Öğe
    Neurologic and biochemical findings and CD4/CD8 ratio in people occupationally exposed to RF and microwave
    (1992) Daşsağ, S.; Balcı, K.; Çelik, Mustafa Salih; Batun, Sabri; Kaplan, Abdurrahman; Bolaman, Zahit; Tekeş, Selahattin; Akdaǧ, Zülküf; 0000-0003-1211-9677
    In this study, we investigated the biological effects of RF (Radio Frequency) and microwave in terms of neurological and biochemical findings, and CD4/CD8 ratio in people that work at broadcasting and television transmitter stations. The study was carried out on 26 people from 20 to 49 years of age, occupationally exposed to nonionizing radiation. First we gave out a questionnaire consisting of 12 questions to everybody under investigation. Secondly, we determined the levels of ALT, AST, LDH, ALP, CK, phosphorus, total protein, albumin cholesterol, uric acid, urea, creatinin, Na, K, and NSE (Neuron Specific Enolase), and also CD4/CD8, albumin/globulin ratios and percentage of serum proteins. The results obtained in this study were statistically compared to a control group.
  • [ X ]
    Öğe
    Sağlıklı postmenopozal kadınlarda kombine 2 mg estradiol valerat ve 2 mg dienogest’in aktive protein C rezistansı üzerindeki etkileri
    (2006) Bolaman, Zahit; Güney, Hasan Yüksel; Onur, Ergün; Kafkas, Samet; Kalkan, Üzeyir; Odabaşı, Ali Rıza; Kalkan, Nurdan Yıldız
    Amaç: Menopozdaki sağlıklı kadınlarda, bir hormon replasman tedavisi (HRT) seçeneği olarak 2 mg estradiol valerat/2 mg dienogest (2 mg EV/2 mg DNG) kullanımının, hemostatik parametreler ve aktive Protein C (APC) sensitivite oranlarına etkisini incelemek amaçlandı. Materyal ve Metot: Çalışmada dört ay süre ile 57 kadına HRT, 50 kadına ise plasebo uygulandı. HRT grubundaki 57 kadının altısında (%10.5), plasebo grubundaki 50 kadının ikisinde (%4.0) Faktör V (FV) Leiden mutasyonu için heterozigotide saptandı. Faktör V Leiden mutasyonu saptanan kadınlardaki aktive Protein C’ye olan potansiyel etkiyi dışlamak için, hemostatik parametreler yalnızca mutasyonu olmayan kadınlarda incelendi. Sonuçlar: Her iki grubun hemostatik parametrelerinin kıyaslanmasında, (2 mg EV/2 mg DNG) alan grupta plasebo grubuna göre, Faktör V ve Protein C seviyelerinde artma, Faktör VIII seviyelerinde azalma oldu. Bu değişiklikler istatistiksel anlamlılığa ulaşmadı. Faktör VII ve serbest Protein S seviyelerinde de anlamlı bir değişiklik olmadı. (2 mg EV/2 mg DNG) tedavisi, Faktör V, VII, VIII, Protein C, serbest Protein S’nin aktive protein C sensitivite oranı ile olan ilişkisini ortaya koyabilmek için çoklu lojistik regresyon analizi yapıldı. Bu bağımsız değişkenlerin APC sensitivite oranı üstüne herhangi anlamlı bir etkisi bulunmadı (p>0.05). Tartışma: Hormon replasman tedavisi seçeneği olarak (2 mg EV/2 mg DNG) kombinasyonu, aktive Protein C sensitivite oranlarında herhangi bir azalmaya neden olmamaktadır. Plasebo ve çalışma grubu değerlendirmelerinde, bu seçenek, edinsel aktive Protein C rezistansına yol açmamaktadır (p>0.05).
  • [ X ]
    Öğe
    Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone
    (2002) Bolaman, Zahit; Köseoǧlu, Mehmet Hicri; Ayyıldız, Orhan; Kadıköylü, Gürhan; Sönmez, Hulki Meltem; Demir, Süleyman; Müftüoğlu, Ekrem
    Fourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methylprednisolone 1000 mg/day intravenously for 5 days. The patients' mean age was 52 ± 10 (range 34-64) and Philadelphia chromosome was positive in all. Five patients (35%) achieved complete remission and four patients (28%) had a partial remission. Overall remission rate was 64%. The mean survival was 11.1 ± 8.6 months (median 13) for all patients, 19.4 ± 4.0 months (median 19) for those achieving a complete remission, 12.50 ± 5.7 months (median 14) for patients with partial remission and 1.8 ± 1.8 months (median 2) for the unresponsive patients. Two of 5 unresponsive patients died early after the second course of remission induction. The treatment regimen was generally well tolerated. Marrow hypoplasia was observed in 9 (64%) patients and 7 (50%) had febrile episodes. Non-myelosupressive toxicity of the regimen was acceptable. Nausea and vomiting were observed in 8 (57%) patients and 3 (21%) patients developed flushing due to cytosine arabinoside. These results suggest that the regimen with mitoxantrone, cytosine arabinoside and high dose methylprednisolone in remission-induction of blastic phase chronic myelogenous leukemia may be a valid option that may also improve overall prognosis.